Alison Armour
Chief Medical Officer CURADH
Alison was an experienced medical and radiation oncologist, with a doctorate in MTR, before joining industry 20 years ago. She is skilled in all stages of drug and diagnostic development. As Chief Medical Officer of Endocyte, Alison clinically developed PSMA617, designing the Phase III VISION registration trial and leading all global regulatory interactions and clinical operations. She supported investigator studies of PSMA617 in combination with DNA repair inhibitors, immune oncology and hormonal therapies as well as obtaining first regulatory approval of PSMA617 based on Phase II data prior to transition to Novartis in December 2018. The drug was approved in 2022 and is now known as Pluvicto.
Seminars
- Using early biodistribution and dosimetry to guide safe, effective dosing for phase zero/fih trials
- Confirming target specificity preclinically to reduce off-target risks and strengthen your IND package
- Aligning radiochemistry with GMP standards early to avoid delays and ensure clinical readiness
This workshop will explore the latest advances in alpha, beta, and Auger emitters for targeted radiopharmaceutical therapy, highlighting isotopes such as actinium-225, lead-212, lutetium-177, terbium-161, radium-223, and iodine-125. Join your peers to examine how their unique radiation properties – range, energy, and DNA damage – can be leveraged to maximize tumor cell killing while minimizing salivary gland and kidney toxicity. Join this session to discover emerging isotopes that could expand the reach of radioligand therapy and enable treatment of tumors previously considered difficult or heterogeneous.
Discussion Points:
- Are you trying to get a bystander effect? If so, what isotope is best to choose to improve overall therapeutic efficacy?
- Alpha VS Beta emitters – Why move towards Alpha emitters when Beta emitters are more established?
- Why pick particular isotopes for particular targets? How to optimize this match for maximized on-target delivery and minimized off-target effects?
- Considering matching time on target with your isotope – how long before you deposit your dose?
- Considering daughter products that might emerge after initial isotope breakdown?
